Vanda Pharmaceuticals (VNDA) Shareholder's Equity Growth (5y) (2014 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.70% |
| Dec 31, 2025 | -6.31% |
| Sep 30, 2025 | 1.13% |
| Jun 30, 2025 | 2.42% |
| Mar 31, 2025 | 4.20% |
| Dec 31, 2024 | 5.56% |
| Sep 30, 2024 | 6.19% |
| Jun 30, 2024 | 12.83% |
| Mar 31, 2024 | 14.34% |
| Dec 31, 2023 | 14.62% |
| Sep 30, 2023 | 15.75% |
| Jun 30, 2023 | 16.53% |
| Mar 31, 2023 | 17.31% |
| Dec 31, 2022 | 32.03% |
| Sep 30, 2022 | 31.63% |
| Jun 30, 2022 | 31.08% |
| Mar 31, 2022 | 31.41% |
| Dec 31, 2021 | 30.91% |
| Sep 30, 2021 | 30.74% |
| Jun 30, 2021 | 31.67% |
| Mar 31, 2021 | 30.61% |
| Dec 31, 2020 | 27.79% |
| Sep 30, 2020 | 24.73% |
| Jun 30, 2020 | 23.58% |
| Mar 31, 2020 | 22.25% |
| Dec 31, 2019 | 20.64% |
| Sep 30, 2019 | 227.57% |
| Jun 30, 2019 | 219.94% |
| Mar 31, 2019 | 67.71% |
| Dec 31, 2018 | 44.23% |
| Sep 30, 2018 | 39.21% |
| Jun 30, 2018 | 118.67% |
| Mar 31, 2018 | 106.12% |
| Dec 31, 2017 | 67.70% |
| Sep 30, 2017 | 53.42% |
| Jun 30, 2017 | 45.60% |
| Mar 31, 2017 | 36.62% |
| Dec 31, 2016 | 31.44% |
| Sep 30, 2016 | 27.94% |
| Jun 30, 2016 | 25.20% |
| Dec 31, 2015 | 28.66% |
| Dec 31, 2014 | 47.50% |